Protease Inhibitors: General Research
- Growth Hormone (rhGH) and Fat Redistribution Syndrome (April 22-25, 1999)
In The 3rd International Conference on Nutrition and HIV Infection, from TheBodyPRO.com
- Treating Fat Redistribution Syndrome (April 22-25, 1999)
In The 3rd International Conference on Nutrition and HIV Infection, from TheBodyPRO.com
- A Multi-Center, Randomized, Open-Label, Comparative Trial of the Clinical Benefit of Switching the Protease Inhibitor by Nevirapine in HAART-Experienced Patients Suffering Lipodystrophy (February 4, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Avascular Necrosis in HIV-Infected Patients: A Potential Link to Protease Inhibitors (February 3, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Mechanisms Responsible for Metabolic Complications of Antiretroviral Therapy (February 3, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Co-Administration of Indinavir 1200 mg with Nelfinavir 1250 mg in a Twice Daily Regimen: Preliminary Safety, PK Activity (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- The Trouble with Fat: Concerns Continue over the Cause and Treatment of Fat Redistribution Syndrome (February 1999)
From Seattle Treatment Education Project
- Incidence of All New Clinical Events in Patients Started on HAART (November 14, 1998)
In The 36th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Co-Administration of Indinavir 1,200 mg (IDV) and Nelfinavir (NFV) 1,250 mg in a Twice Daily Regimen: Preliminary Safety, Pharmacokinetic (PK) and Anti-Viral Activity (November 14, 1998)
In The 36th Annual Meeting of the Infectious Diseases Society of America, from TheBodyPRO.com
- Successful Standard Treatment for Lipid Abnormalities (October 2, 1998)
From AIDS Treatment News
- Incidence and Factors Associated with the Development of Hypercholesterolemia and Hyperglycemia in HIV-Infected Patients Using a Protease Inhibitor (September 26, 1998)
In The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Gemfibrozil Effectively Lowers Protease-Associated Hypertriglyceridemia in HIV-Infected Patients (September 25, 1998)
In The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Protease Inhibitors and Reconstitution of the Immune System (August 1998)
In HIV Newsline, from San Francisco General Hospital
- Protease Inhibitor-Associated Hyperglycemia: Results of Switching from Indinavir to Nelfinavir (July 1, 1998)
In The 12th International AIDS Conference, from TheBodyPRO.com
- What Have We Learned About Lipodystrophy, High Cholesterol, Diabetes, and Long Term Complications of Protease Inhibitors? (June 29 and 30, July 1, 1998)
In The 12th International AIDS Conference, from TheBodyPRO.com
- Double Protease Inhibitor Combinations (April 1998)
In Project Inform Perspective
- Advances Made Towards Simpler Protease Inhibitor Regimens (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Antiretroviral Therapy: Unique Adverse Effects of Protease Inhibitors (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Maintaining Protease Inhibitor Therapy Setting (February 2, 1998)
From Seattle Treatment Education Project
- Half-full or Half-empty: No Simple Answer on Protease Inhibitor Failure (October 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Double Protease Inhibitor Combinations (September 28-October 1, 1997)
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
